Humacyte

Humacyte Days Payable Outstanding

The Days Payable Outstanding (DPO) of Humacyte (HUMA) as of Nov 21, 2026 is 115.71. In the previous year, Days Payable Outstanding (DPO) was 227.93 — a change of -49.24% (lower).

Days Payable Outstanding

115.71

YoY

-49.24%

Last updated:

Days Payable Outstanding (DPO) of Humacyte is 2025 115.71 . Days Payable Outstanding (DPO) of Humacyte was 2024 227.93 . It decreases by -49.24% lower compared to the previous year.

The Humacyte Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2019
15.80 USD
Jan 1, 2020
15.35 USD
Jan 1, 2021
12.46 USD
Jan 1, 2022
70.52 USD
Jan 1, 2023
30.95 USD
Jan 1, 2024
227.93 USD
Jan 1, 2025
115.71 USD
The Humacyte Days Payable Outstanding history
YEARDays Payable OutstandingYoY
115.71-49.24%
227.93+636.58%
30.95-56.12%
70.52+466.00%
12.46-18.82%
15.35-2.84%
15.80—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humacyte Stock analysis

What does Humacyte do? Humacyte, Inc. develops and manufactures off-the-shelf, universally implantable bioengineered human tissues and advanced tissue constructs. The company focuses on human acellular vessels (HAVs) targeting vascular repair, reconstruction, and replacement markets, including vascular trauma, AV access for hemodialysis, peripheral arterial disease, and coronary artery bypass grafting. HAVs are also being developed for pediatric heart surgery and cellular therapies like pancreatic islet cell transplantation for Type 1 diabetes. The company's technology platform uses primary human aortic vascular cells to mimic human physiology. Humacyte's products are sold to healthcare providers and medical institutions for surgical procedures requiring tissue replacement. The vascular repair and hemodialysis markets represent key segments where HAVs address unmet clinical needs. Pediatric heart surgery applications target specialized medical centers, while cellular therapy delivery focuses on diabetes treatment centers. The company's novel manufacturing paradigm enables universal implantability without immune rejection. The firm's revenue streams derive from the sale of HAVs for vascular procedures and their expansion into pediatric and cellular therapy applications. Market segments include vascular surgery, nephrology for hemodialysis access, and endocrinology for diabetes treatment. HAVs are positioned as a solution for patients requiring tissue grafts with reduced risk of rejection compared to traditional methods. Humacyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humacyte stock

Days Payable Outstanding (DPO) of Humacyte is 115.71 in 2025.

Days Payable Outstanding (DPO) of Humacyte changed from 227.93 to 115.71, representing a -49.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) Humacyte since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s Humacyte with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Humacyte

All Key Metrics — Humacyte